Clinical application of a bioactive nano-hydroxyapatite/polyamide 66 interbody fusion cage
Wang Mao-yuan
Xie Rui-lian
He Chun-lei
Liu Wu-yang
Huang Wei-min
Gao Hui
Abstract： BACKGROUND:There are various commonly used interbody fusion methods, such as autologous bone, <br> al ograft bone and titanium-based posterior lumbar interbody fusion, and each method has its own advantages and disadvantages. <br> OBJECTIVE:To observe the clinical efficacy of a bioactive nano-hydroxyapatite/polyamide 66 fusion cage in posterior lumbar interbody fusion for the treatment of lumbar disease. <br> METHODS:A retrospective case analysis was conducted on 16 cases treated with posterior lumbar interbody <br> fusion at the Department of Orthopedic, the First Affiliated Hospital of Gannan Medical University from July 2010 to December 2011, and al the patients were implanted with nano-hydroxyapatite/polyamide 66 biological activity fusion cage. <br> RESULTS AND CONCLUSION:Al the patients were fol owed-up for 10-24 months, and the lumbar pain was significant improved, the lumbar visual analogue score, lumbar Japanese Orthopaedic Association score and Oswestry disability index score were significantly improved during the final fol ow-up period (P<0.05). No internal fixation loosing or broken observed in al the patients during final fol ow-up, and al the patients obtained bone <br> fusion without nano-hydroxyapatite/polyamide 66 fusion cage displacement or subsidence. The results indicate that nano-hydroxyapatite/polyamide 66 fusion cage for the treatment of posterior lumbar interbody fusion can <br> reconstruct the lumbar stability and provide immediate stability after implantation, and has good biological activity.
Keywords：biomaterialsnanobiomaterialsorthopedic biomaterialsnano-hydroxyapatitepolyamide 66interbody fusion cageinterbody fusionbiocompatibility
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 6179-6182 )